Q2 2025 Trevi Therapeutics Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $7.3 (+0.41%)

Transcript 10-Q8-K

Key Points

Positve

Trevi Therapeutics Inc (TRVI) reported positive data readouts from both the coral trial for chronic cough in IPF patients and the river trial for RCC patients.
The company successfully raised approximately $115 million in capital, resulting in a total cash and investments of approximately $204 million as of June 2025.
The coral trial showed statistically significant improvements in quality of life for patients, with marked improvements in the LCQ scores.
Trevi Therapeutics Inc (TRVI) is well-positioned to execute its strategy with a strong financial runway into 2029, enabling the funding of multiple phase 3 trials.
The company is actively preparing for phase 3 trials and has plans to expand its market opportunity by targeting non-IPF interstitial lung diseases, potentially doubling its market size.

Negative

Trevi Therapeutics Inc (TRVI) reported a net loss of $12.3 million for the second quarter of 2025, similar to the previous year's quarter.
R&D expenses decreased, but general and administrative expenses increased due to higher professional fees and personnel costs.
The company faces challenges in aligning with regulatory authorities and ensuring the successful execution of upcoming clinical trials.
There is uncertainty regarding the outcomes of ongoing phase 1 studies, including potential drug-drug interactions with antifibrotics.
The company must manage potential placebo effects and other challenges in the longer follow-up phase 3 trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TRVI.OQ - Trevi Therapeutics Inc
Q2 2025 Trevi Therapeutics Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Trevi Therapeutics 2nd quarter 2025 earnings conference call.

At this time, all participants will be in listen-only mode.

Should you need assistance, please signal a conference specialist by pressing the star key followed by 0.

After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone.

To withdraw your question, please press 2.

Please note this event is being recorded.

Various remarks that management makes during this conference call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.